BSL 4

Drug Profile

BSL 4

Latest Information Update: 16 Nov 1998

Price : $50

At a glance

  • Originator Dainippon Ink & Chemicals
  • Class Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 16 Nov 1998 Discontinued-Preclinical for HIV infections treatment in Japan (PO)
  • 31 Jul 1998 No-Development-Reported for HIV infections treatment in Japan (PO)
  • 26 Nov 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top